Latest News

GE Healthcare announced clearance from the Food and Drug Administration (FDA) for its new Vivid^TM T8 cardiovascular ultrasound device. The 58 kilograms, mobile system features innovative quantitative features, stress echo and TEE capabilities, delivering exceptional value to healthcare providers looking for an affordable ultrasound system.

GE has enhanced the reach of the Vivid T8 by combining the established cardiac imaging capabilities of GE Vivid systems with exceptional shared services performance of the company's LOGIQ^TM systems. The Vivid T8, cardiovascular ultrasound system is rugged, reliable, robust, and rich with features, yet still affordable and convenient to use.

"Performance, complete echocardiography features, shared services and reliability were the key priorities in developing the Vivid T8," said Al Lojewski, GM of Cardiovascular Ultrasound for GE Healthcare. "In developing the system, we put it through more than 20 hours of intense vibration, shock and thermal testing to ensure its reliability in the settings outlined by our customers. The result is a value system unlike any other we've commercialized at GE. With the growing global crisis of cardiovascular disease, we wanted to develop an affordable, reliable solution that could potentially allow clinicians around the world increased access to high performance ultrasound.

Scanning with Convenience

Designed to be easy to use yet clinically versatile, the T8 features an intuitive user interface with touch-screen capabilities, rotary dials and patient management buttons with the look and feel of a true Vivid console. Additionally, it provides access to up to four transducer ports allowing increased, easier access to more clinical procedures.

The Vivid T8 system allows healthcare providers access to advanced quantitative tools and delivers exceptional shared service image quality, with options to customize the system to help fit each healthcare provider's needs.